Ambitious Amryt To File Butterfly Skin Drug Imminently

Irish Firm Eyes 2021 Launches For Filsuvez

The Dublin-based drugmaker, powered by climbing revenues of Lojuxta and Myalept, is preparing its launch teams for Filsuvez, which has the potential to become the first treatment approved for epidermolysis bullosa and the company is banking on speedy regulatory reviews.

butterfly
A treatment for butterfly skin could land soon • Source: Shutterstock

Amryt Pharma is confident of repeating last year's successes in 2021, with preparations well underway for the possible launch of Filsuvez, which has the potential to become the first treatment approved for epidermolysis bullosa (EB), a rare genetic condition where skin can tear at the slightest touch.

The Irish company, which is listed on the NASDAQ and London's AIM market, expects to submit Filsuvez (also known as...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Rare Diseases

More from Scrip